ClinicalTrials.gg
CompletedNCT02107092Updated Aug 15, 2018Results posted

Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.

A Phase 3 interventional study of Sodium Zirconium Cyclosilicate in Hyperkalemia, sponsored by ZS Pharma, Inc.. Completed at 49 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-15.

Sponsored by ZS Pharma, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.

Enrollment
12th of 27
123 · median 120
Started
2014
with 2 others
Phase 3
12 of 27
none open now
Registered
2nd of 27
by date
Lead sponsor
3 of 27
ZS Pharma, Inc.

Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 12th largest by enrollment, is one of 3 that started in 2014, is one of 12 in phase 3, and was the 2nd registered.

Hyperkalemia

134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.

Browse Hyperkalemia studies →

Open to participants now

3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sodium zirconium cyclosilicate

sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, or all of them as a file.
02

Study summary

Subjects who completed the Double-blind Randomized Maintenance Phase (DBRMP) Study Day 29 visit in ZS-004 (NCT 02088073) and have an i-STAT potassium value that is 3.5 to 6.2 mmol/l inclusive or who discontinued during ZS-004 due to hypo- or hyperkalemia in the DBRMP and have a mean i-STAT potassium value from two consecutive measurements at 0 and 60 minutes on Acute Phase Day 1/Maintenance Phase Day 1 that is 3.5 to 6.2 mmol/l inclusive may have the option to participate in ZS-004E (NCT 021070920). Subjects who discontinued from study ZS-004 due to any other reasons (e.g. adverse events, poor compliance, investigator decision) will not be entered into study ZS-004E. All subjects who continue into the extension study must begin dosing within two (2) days after the last dose of investigational product in ZS-004.

Read the detailed description

All subjects with i-STAT potassium values between 3.5-5.5 mmol/l, inclusive at the ZS-004 (NCT 02088073) DBRMP Study Day 29 visit, who continue directly into the open-label extension study ZS-004E (NCT 021070920), will enter the Maintenance Phase (MP) and start on open-label ZS at a dose of 10g qd. All subjects with i-STAT potassium values > 5.5 mmol/l at the ZS-004 DBRMP Study Day 29 visit will undergo an acute treatment phase (AP) where they will receive ZS 10g three times a day (tid) for 24 (3 doses) or 48 hours (6 doses). If the subject's i-STAT potassium is between 3.5-5.0 mmol/l, inclusive after 24 (AP Study Day 2) or 48 hours (AP Study Day 3), the subject will enter the MP at a starting dose of 10g qd.

For subjects who discontinued during ZS-004 DBRMP due to hypo- or hyperkalemia baseline potassium values will be determined within 1 day of administration of the first dose in the ZS-004E extension study by taking two (2) consecutive i-STAT potassium measurements at 0 and 60 minutes (± 10 minutes). If the mean i-STAT value is between 3.5 - 5.5 mmol/l, inclusive, the subject will enter directly into the MP and receive 10g ZS qd; if the mean i-STAT potassium value is > 5.5 mmol/l, the subject will enter the AP. If i-STAT potassium values are still >5.0 mmol/l on the morning of AP Study Day 3, subjects will not enter the MP but will be referred to their normal health care provider for standard of care.

If the i-STAT potassium value increases above 5.5 mmol/l during the MP with treatment at 10g qd, the dose can be increased to15g qd. Conversely, if S-K decreases to between 3.0-3.4 mmol/l, inclusive, the dose of ZS can be decreased in 5g qd, decrements. If a subject is on a 5g qd dose and still develops blood potassium i-STAT values between 3.0 - 3.4mmol, inclusive the dose can be reduced to 5g every other day.

Subjects will receive up to 11 months of treatment with open-label ZS.

03

Conditions studied

  • Hyperkalemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written .
  • Completed the ZS-004 DBRMP Study Day 29 visit or discontinued study ZS-004 during the DBRMP due to hypo- or hyperkalemia and able to start dosing in ZS-004E within two (2) days after the last dose of product in ZS-004.
  • Subject must have an i-STAT potassium value that is 3.5 to 6.2 mmol/l inclusive at the ZS-004 DBRMP Study Day 29 visit or a mean i-STAT potassium value from two consecutive measurements at 0 and 60 minutes on Acute Phase Day 1/Maintenance Phase Day 1 that is 3.5 to 6.2 mmol/l inclusive if the subject discontinued study ZS-004 during the DBRMP due to hypo- or hyperkalemia .

Exclusion criteria

Exclusion Criteria:

  • Pseudohyperkalemia signs and symptoms, such as excessive fist clenching hemolyzed blood specimen, history of severe leukocytosis or thrombocytosis.
  • Subjects who received alternative treatment for hyperkalemia while participating in study ZS-004.
  • Subjects with a of less than 3 months.
  • Subjects who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the subjects' tasks associated with the protocol.
  • Women who are pregnant, lactating, or planning to become pregnant.
  • Subjects with diabetic ketoacidosis.
  • Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.
  • Known or previous anaphylaxis to ZS or to components thereof.
  • Treatment with a drug or device other than ZS within the last 30 days that has not received regulatory approval at the time of study entry.
  • Subjects with cardiac arrhythmias that require immediate treatment.
  • Subjects on dialysis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Sodium Zirconium Cyclosilicate

    Open label oral administration of sodium zirconium cyclosilicate 10g once daily for 11 months.

    Drug: Sodium Zirconium Cyclosilicate

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects With Average Serum Potassium Values ≤ 5.1 mmol/L

    The proportions of subjects with average serum potassium (S-K) values ≤ 5.1 mmol/L during Extended Dosing Study Days 8 to 337, inclusive

    Time frame: 11 months

Secondary outcomes

  1. Proportion of Subjects With Average Serum Potassium Values ≤ 5.5 mmol/L

    The proportions of subjects with average S-K values ≤ 5.5 mmol/L during Extended Dosing Study Days 8 to 337, inclusive

    Time frame: 11 months

07

Results

Posted Aug 15, 2018

Participant flow

Participants took part in the study at 30 outpatient sites in the United States, Australia and South Africa from 10 May 2014 to 14 July 2015.

Participant flow — Overall Study
MilestoneExtended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD
Started123
Completed79
Not completed44
Withdrew: Miscellaneous3
Withdrew: Subject compliance3
Withdrew: Hypo-or hyperkalemia2
Withdrew: Met ecg withdrawal criteria3
Withdrew: Physician decision3
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject9
Withdrew: Adverse event7
Withdrew: Expected progression of ckd12

Outcome measures

PrimaryProportion of Subjects With Average Serum Potassium Values ≤ 5.1 mmol/L

The proportions of subjects with average serum potassium (S-K) values ≤ 5.1 mmol/L during Extended Dosing Study Days 8 to 337, inclusive

Time frame:
11 months
Reported as:
Number · Proportion of Participants
Proportion of Subjects With Average Serum Potassium Values ≤ 5.1 mmol/L
Proportion of ParticipantsExtended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD
ED Study Day 80.875 (0.802 to 0.928)
ED Study Day 150.822 (0.741 to 0.886)
ED Study Day 220.797 (0.713 to 0.865)
ED Study Day 290.862 (0.786 to 0.919)
ED Study Day 360.848 (0.768 to 0.909)
ED Study Day 430.793 (0.705 to 0.864)
ED Study Day 500.796 (0.708 to 0.868)
ED Study Day 570.766 (0.675 to 0.843)
ED Study Day 850.807 (0.709 to 0.833)
ED Study Day 1130.798 (0.696 to 0.877)
ED Study Day 1410.815 (0.713 to 0.892)
ED Study Day 1690.771 (0.656 to 0.863)
ED Study Day 1970.809 (0.695 to 0.894)
ED Day Study 2250.846 (0.735 to 0.924)
ED Study Day 2530.778 (0.655 to 0.873)
ED Study Day 2810.833 (0.715 to 0.917)
ED Study Day 3090.828 (0.706 to 0.914)
ED Study Day 3370.843 (0.714 to 0.930)
ED Study Day 337/Exit0.783 (0.699 to 0.853)
ED Study Days 8-337 Average0.883 (0.812 to 0.935)
SecondaryProportion of Subjects With Average Serum Potassium Values ≤ 5.5 mmol/L

The proportions of subjects with average S-K values ≤ 5.5 mmol/L during Extended Dosing Study Days 8 to 337, inclusive

Time frame:
11 months
Reported as:
Number · Proportion of Participants
Proportion of Subjects With Average Serum Potassium Values ≤ 5.5 mmol/L
Proportion of ParticipantsExtended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD
ED Study Day 80.950 (0.894 to 0.981)
ED Study Day 150.932 (0.871 to 0.970)
ED Study Day 220.975 (0.927 to 0.995)
ED Study Day 290.957 (0.902 to 0.986)
ED Study Day 360.955 (0.899 to 0.985)
ED Study Day 430.946 (0.886 to 0.980)
ED Study Day 500.935 (0.871 to 0.974)
ED Study Day 570.944 (0.882 to 0.979)
ED Study Day 850.943 (0.872 to 0.981)
ED Study Day 1130.940 (0.867 to 0.980)
ED Study Day 1410.938 (0.862 to 0.980)
ED Study Day 1690.929 (0.841 to 0.976)
ED Study Day 1970.941 (0.856 to 0.984)
ED Day Study 2250.985 (0.917 to 1.000)
ED Study Day 2530.937 (0.845 to 0.982)
ED Study Day 2810.950 (0.861 to 0.990)
ED Study Day 3090.914 (0.810 to 0.971)
ED Study Day 3370.980 (0.896 to 1.000)
ED Study Day 337/Exit0.942 (0.884 to 0.976)
ED Study Days 8-337 Average1.000 (0.970 to 1.000)

Adverse events

Collected over Eleven months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZS (Sodium Zirconium Cyclosilicate) QD Extended Phase Dosing—24/123 (19.5%)82/123 (66.7%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventZS (Sodium Zirconium Cyclosilicate) QD Extended Phase Dosing
Cardiac failure congestiveCardiac disorders2/123
Abdominal PainGastrointestinal disorders2/123
PneumoniaInfections and infestations2/123
Urinary tract infectionInfections and infestations2/123
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/123
AnaemiaBlood and lymphatic system disorders1/123
Acute myocardial infarctionCardiac disorders1/123
Cardiac failureCardiac disorders1/123
Myocardial infarctionCardiac disorders1/123
Retinal artery occlusionEye disorders1/123
Most frequent other events
Showing 10 of 27
Most frequent other events
EventZS (Sodium Zirconium Cyclosilicate) QD Extended Phase Dosing
HypertensionVascular disorders15/123
Urinary tract infectionInfections and infestations11/123
Oedema peripheralGeneral disorders10/123
ConstipationGastrointestinal disorders7/123
AnaemiaBlood and lymphatic system disorders6/123
Muscle spasmsMusculoskeletal and connective tissue disorders6/123
Upper respiratory tract infectionInfections and infestations5/123
DiarrhoeaGastrointestinal disorders4/123
NauseaGastrointestinal disorders4/123
VomitingGastrointestinal disorders4/123

Baseline characteristics

2 subjects did not have any S-K measurements during the ED phase due to early termination and are excluded from baseline characteristics

Age, Continuous
Age, Continuous(Years)Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD
Mean63.7 ± 12.29
Sex: Female, Male
Sex: Female, Male(Participants)Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD
Female51
Male70
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD
Asian2
Black or African American11
White107
Other1
Study ZS-004 Acute Phase S-K baseline
Study ZS-004 Acute Phase S-K baseline(Participants)Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD
< 5.5 mmol/L54
5.5-< 6.0 mmol/L53
≥ 6.0 mmol/L14
Acute Phase eGFR at baseline
Acute Phase eGFR at baseline(Participants)Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD
<60 mL/min90
≥ 60 mL/min31
Cormordid conditions and concomitant medications which may contirubute to hyperkalemia
Cormordid conditions and concomitant medications which may contirubute to hyperkalemia(Participants)Extended Dosing Phase: ZS (Sodium Zirconium Cyclosilicate) QD
RAAS inhibitor medication83
Diabetes mellitus80
Chronic kidney disease76
Heart failure50
08

Study locations

49 sites
  • Anniston, Alabama 36207, United States
  • Huntsville, Alabama 35801, United States
  • Scottsboro, Alabama 35768, United States
  • Phoenix, Arizona 85027, United States
  • Tempe, Arizona 85284, United States
  • Hawaiian Gardens, California 90716, United States
  • Los Angeles, California 90022, United States
  • Paramount, California 90723, United States
  • Riverside, California 92505, United States
  • Atlantis, Florida 33462, United States
  • Bradenton, Florida 34208, United States
  • Brandon, Florida 33511, United States
  • Brooksville, Florida 34601, United States
  • DeLand, Florida 32720, United States
  • Edgewater, Florida 32132, United States
  • Miami Lakes, Florida 33014, United States
  • Miami Lakes, Florida 33018, United States
  • Miami, Florida 33015, United States
  • Miami, Florida 33125, United States
  • New Smyrna Beach, Florida 32168, United States
  • Ocala, Florida 34471, United States
  • Summerfield, Florida 34491, United States
  • Tampa, Florida 33607, United States
  • Tampa, Florida 33614, United States
  • Winter Park, Florida 32789, United States
  • Columbus, Georgia 31901, United States
  • Decatur, Georgia 30030, United States
  • Evergreen Park, Illinois 60805, United States
  • Joliet, Illinois 60435, United States
  • Shreveport, Louisiana 71101, United States
  • Auburn, Maine 04210, United States
  • Chesterfield, Michigan 48047, United States
  • Kansas City, Missouri 64411, United States
  • Las Vegas, Nevada 89115, United States
  • Flushing, New York 11355, United States
  • Altoona, Pennsylvania 16602, United States
  • Providence, Rhode Island 02903, United States
  • Orangeburg, South Carolina 29118, United States
  • Sumter, South Carolina 29150, United States
  • Chattanooga, Tennessee 37408, United States
  • San Antonio, Texas 78229, United States
  • Gosford, New South Wales, Australia
  • Woolloongabba, Queensland, Australia
  • Heidelberg, Victoria, Australia
  • Melbourne, Victoria, Australia
  • Parkville, Victoria, Australia
  • Meyerspark, South Africa
  • Port Elizabeth, South Africa
  • Somerset West, South Africa
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Jul 2015, 14 months.

Results were first posted in Aug 2018, 3 years after primary completion. A results delay was requested in Nov 2015.

Of 18 phase 3 interventional studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2014
First posted
Apr 8, 2014
StartActual
May 31, 2014
Primary completionActual
Jul 31, 2015
CompletionActual
Aug 31, 2015
Results delay requested
Nov 12, 2015
Results first posted
Aug 15, 2018
Last update
Aug 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02107092
Lead sponsor
ZS Pharma, Inc.
Responsible party
Sponsor
First posted
Apr 8, 2014
Start date
May 31, 2014
Primary completion
Jul 31, 2015
Completion
Aug 31, 2015
Results posted
Aug 15, 2018
Last update
Aug 15, 2018

Study contacts

Henrik Rasmussen, MD, PhD
study chair · ZS Pharma, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium zirconium cyclosilicate

Start the discussion